Back to Search
Start Over
Gene-edited lymphocytes and the path toward 'off-the-shelf' therapy against cervical cancer.
- Source :
- Cancer Vaccine Week; 3/18/2024, p23-23, 1p
- Publication Year :
- 2024
-
Abstract
- Scientists at Juntendo University School of Medicine in Japan have made a breakthrough in developing a potential therapy for cervical cancer. They have successfully engineered rejuvenated cytotoxic T lymphocytes (rejTs) from induced pluripotent stem cells (iPSCs) to target HPV-specific antigens expressed in cervical cancer cells. By using CRISPR-Cas9 gene editing, the researchers were able to modify the iPSCs to evade attacks from the patient's immune system. In preclinical experiments, the gene-edited rejTs showed promising results in fighting cervical cancer cells while evading immune responses. The researchers plan to conduct a clinical trial in 2024. [Extracted from the article]
- Subjects :
- CERVICAL cancer
LYMPHOCYTES
MONONUCLEAR leukocytes
CD8 antigen
CD antigens
Subjects
Details
- Language :
- English
- ISSN :
- 15436810
- Database :
- Complementary Index
- Journal :
- Cancer Vaccine Week
- Publication Type :
- Periodical
- Accession number :
- 176051968